三生制药将一款处于临床阶段的双特异性抗体药物以60.5亿美元的价格授权给辉瑞;恒瑞医药与葛兰素史克(GSK)达成潜在价值125亿美元的交易;信达生物与武田制药就三款产品达成114亿美元的交易……当下,中国生物医药行业的交易纪录正被本土创新力量持续刷新。 这也印证着,跨国药企在华的研发战略正经历一场悄然却深刻的转型:跨国药企不再仅仅满足于成为成熟产品的商业化落地者,而是将触角延伸至更早期的本土...
Source Link三生制药将一款处于临床阶段的双特异性抗体药物以60.5亿美元的价格授权给辉瑞;恒瑞医药与葛兰素史克(GSK)达成潜在价值125亿美元的交易;信达生物与武田制药就三款产品达成114亿美元的交易……当下,中国生物医药行业的交易纪录正被本土创新力量持续刷新。 这也印证着,跨国药企在华的研发战略正经历一场悄然却深刻的转型:跨国药企不再仅仅满足于成为成熟产品的商业化落地者,而是将触角延伸至更早期的本土...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.